Partnerships will Collaborate on Procurement Models, Logistics Management, Market Developments, Joint Projects, and Information Communication

HONG KONG, 8 March 2022 – Zhaoke Ophthalmology Limited (“Zhaoke Ophthalmology” or “the Company”, SEHK: 6622), a leading ophthalmic pharmaceutical company dedicated to the research and development, manufacturing and commercialization of therapies that address significant unmet medical needs, is pleased to announce today that Zhaoke Ophthalmology has signed strategic partnership agreements with China’s leading pharmaceutical supply chain service companies - Sinopharm Distribution Centre which represents Sinopharm Group Co., Ltd. (“Sinopharm”), Shanghai Pharmaceuticals Co., Ltd. (“Shanghai Pharmaceuticals”), and China Resources Pharmaceutical Commercial Co., Ltd. (“CR Pharmaceutical Commercial”) (hereinafter referred to as “The Partners”) respectively. Zhaoke Ophthalmology and the three leading Chinese pharmaceutical companies will collaborate on multiple aspects including procurement models, logistics management, market developments, joint projects, and information communication.

Procurement Models

Zhaoke Ophthalmology will provide The Partners with its pharmaceutical products that comply with national quality standards, while the Partners will leverage the resources of their affiliates to integrate and collaborate on business decisions with the Company.

Logistics Management

Zhaoke Ophthalmology and The Partners will strengthen their combined logistics management by sharing best practice information and experience, actively exploring third-party logistics and a multi-warehouse operation cooperation model, and improving the efficiency of logistics and distribution.

Market Developments

With the support of the sales network of The Partners, Zhaoke Ophthalmology will increase the coverage of its products, and develop retail channels and value-added channel services. As a result, patients will have broader access to treatments and Zhaoke Ophthalmology’s patient-centred services will be expanded.

Joint Projects

Zhaoke Ophthalmology will work together with The Partners to collaborate on product distribution, particularly in online channels. Meanwhile, Zhaoke Ophthalmology and The Partners will explore opportunities linking healthcare and internet services, creating innovate business models to leverage their combined resources, with an aim to unite traditional pharmaceutical manufacturing and supply chain services with emerging internet-based medical care to develop a new patient-centred medical service system.

Information Communication

Zhaoke Ophthalmology and The Partners will jointly establish an electronic information platform to share information such as market trends, as well as other publicly available information.

Dr. Li Xiaoyi (Benjamin), Chairman of the Board of Directors, Executive Director and CEO of Zhaoke Ophthalmology, said, “our partnership with three leading Chinese pharmaceutical supply chain companies - Sinopharm, Shanghai Pharmaceuticals and CR Pharmaceutical Commercial, is of great significance to Zhaoke Ophthalmology, as it will provide us with an efficient and powerful distribution network for our products to be commercialized. The collaborations are an important step in the progress of our commercialization strategy, starting from the R&D stage right through to the sales and marketing of treatments for patients. We look forward to continuing to expand on the partnerships with Sinopharm, Shanghai Pharma and CR Pharmaceutical, to leverage our combined services and achieve mutual benefits.”

Dr. Lit-Fui Lau, Chief Scientific Officer of Zhaoke Ophthalmology, said, “our three partners have combined supply chains and pharmacy chain networks that cover the whole country. Their servicing models make them highly sought after and reliable partners for pharmaceutical enterprises in China. In the near future, when Zhaoke Ophthalmology begins to commercialize its products, we will be able to leverage the resources of these partnerships to benefit the vast number of Chinese patients with eye diseases. In addition to collaborating on channel distribution and treatment coverage area, we will also explore additional areas of cooperation, ranging from R&D, clinical studies, product imports, e-commerce and retail sales support, commercial insurance, tendering and government affairs.”